GRAIL, Inc. (GRAL) Stock Analysis

GRAIL sold more than 185,000 Galleri multi-cancer early detection tests in 2025, bringing cumulative commercial volumes to over 475,000 since the mid-2021 launch, while reporting a net loss of $408.4 million and an accumulated deficit of $10.2 billion at December 31, 2025. The last module of a Pre-Market Approval application for Galleri was submitted to the FDA in January 2026, incorporating data from the PATHFINDER 2 Initial Results and the NHS-Galleri Prevalent Screening Round. Galleri constitutes substantially all of GRAIL's current revenue.

GRAIL sells Galleri as a laboratory developed test accessible to self-insured employers, digital health platforms, certain third-party payors, and life insurance providers in the United States; government reimbursement through Medicare and Medicaid was not in place as of December 31, 2025. In February 2026, a new U.S. law created a Medicare coverage benefit category for MCED tests, with CMS authorized to initiate coverage as early as January 1, 2029, phased in starting with those aged 50-65 and expanding by one year-age annually, subject to a CMS national coverage determination process. GRAIL also generates limited revenue from a precision oncology platform offered on a research-use-only basis to biopharmaceutical partners; in late 2025, one partner terminated a Phase 3 trial for which GRAIL's methylation technology was used as a potential companion diagnostic. The company's laboratory infrastructure processed over 800,000 tests across clinical and commercial programs through year-end 2025.